Back to News
Top StoriesMarketWatch5h ago

The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

Read Full Article on MarketWatch

Content sourced from MarketWatch. Not financial advice.